



1641
MSB-7272 U.S.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Clark Pan et al.,

Serial Number: 09/671,773

Filed: 09/27/2000

Title: "Pituitary Adenylate Cyclase Activating Peptide (PACAP)

Receptor 3 (R3) Agonists and their Pharmacological Methods Of Use."

H3
Plunk
4/12/02
TECH CENTER 1600
APR 10 2002
RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. 1.56 and 37 C.F.R. 1.97-1.99, Applicants request that the references listed on the attached Form PTO-1449 be made of record in the above-identified application.

Attorney for Applicants

Melissa A. Shaw

Melissa A. Shaw
Reg. No. 38,301

Bayer Corporation
Law and Patent Department
800 Dwight Way
P.O. Box 1986
Berkeley, CA 94701
(510) 705-7901



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TECH CENTER 1600/2900

APR 10 2002

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application	09/671,773	
	Filing Date	September 27, 2000	
	First Named	Clark Pan	
	Group Art Unit	1641	
	Examiner Name	Kimberly White	
Total Number of Pages in This Submission	4	Attorney Docket Number	MSB-7272 US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Includes copies of all references listed on form 1449.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Melissa A. Shaw, Reg. 38,301 Attorney for Applicants Bayer Corporation
Signature	<i>Melissa A. Shaw</i>
Date	April 5, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:			
			April 5, 2002
Typed or printed name	Leigh E. Johnson		
Signature	<i>Leigh E. Johnson</i>	Date	4/5/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.